Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma, Alveolar Soft Part × cediranib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Uterine Cervical Neoplasms 2 Rectal Neoplasms 2 Endometrial Neoplasms 2 Uveal Melanoma 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pleural Effusion, Malignant 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 2 pazopanib 2 Sunitinib 2 Radiotherapy 2 selinexor 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 ixazomib 1 cediranib 1 Zoledronic Acid 1 Radiotherapy, Intensity-Modulated 1 Radiation Dose Hypofractionation 1 Polymerase Chain Reaction 1 Nivolumab 1 Neoadjuvant Therapy 1 Methotrexate 1 Ifosfamide 1 Gene Expression Profiling 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Diathermy 1 Dasatinib 1 Dactinomycin 1 Dacarbazine 1 Cisplatin 1 Blotting, Western 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01337401 2019-01-24

CASPS

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Sarcoma, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon ⚡